menu
    • menu
    [{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Techdow USA","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Fosaprepitant","moa":"NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Techdow USA","highestDevelopmentStatusID":"15","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Techdow USA"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Biocytogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"NTB003","moa":"IGF-1 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"5","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inventiva Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Lanifibranor","moa":"PPAR-alpha\/delta\/gamma","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.28000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Chia Tai Tianqing Pharmaceutical Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Chia Tai Tianqing Pharmaceutical Group

    Menu

    Chia Tai Tianqing Pharmaceutical Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chia Tai Tianqing Pharmaceutical Group

                            China arrow
                            ACS Fall 2025
                            Not Confirmed

                            Chia Tai Tianqing Pharmaceutical Group

                            China arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanifibranor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Recipient : Inventiva Pharma

                            Deal Size : $282.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Inventiva Receives $10 Million Milestone Payment from CTTQ

                            Details : The collaboration aims to develop and commercialize IVA 337 (lanifibranor), if approved, Inventiva’s proprietary compound, for the treatment of nonalcoholic steatohepatitis.

                            Product Name : IVA337

                            Product Type : Other Small Molecule

                            Upfront Cash : $12.0 million

                            July 07, 2025

                            Lead Product(s) : Lanifibranor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Recipient : Inventiva Pharma

                            Deal Size : $282.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Chia Tai Tianqing Pharmaceutical Group

                            China arrow
                            ACS Fall 2025
                            Not Confirmed

                            Chia Tai Tianqing Pharmaceutical Group

                            China arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTB003

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Recipient : Biocytogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for NTB003

                            Details : NTB003 is a second-generation fully human anti-IGF-1R monoclonal antibody, being investigated for thyroid eye disease.

                            Product Name : BCG009

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 04, 2025

                            Lead Product(s) : NTB003

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Recipient : Biocytogen

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Chia Tai Tianqing Pharmaceutical Group

                            China arrow
                            ACS Fall 2025
                            Not Confirmed

                            Chia Tai Tianqing Pharmaceutical Group

                            China arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosaprepitant

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Techdow USA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Techdow USA and CTTQ Pharma Announce Collaboration Agreement and Launch of Fosaprepitant for Injection

                            Details : Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.

                            Product Name : Emend-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 22, 2023

                            Lead Product(s) : Fosaprepitant

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Techdow USA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth